You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Umbralisib

Showing 1 - 20 of 20
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Pembrolizumab
  • Umbralisib
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Waldenstrom Macroglobulinemia Trial in United States (Umbralisib)

Completed
  • Waldenstrom Macroglobulinemia
  • Umbralisib
  • Washington, District of Columbia
  • +3 more
Oct 19, 2022

Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Fort Myers, Saint Petersburg, Nashville (Ublituximab, Umbralisib)

Terminated
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Fort Myers, Florida
  • +2 more
Jul 20, 2022

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
Aug 19, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jul 31, 2022

Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +2 more
Aug 19, 2022

Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL Trial in New York (Umbralisib, Ublituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • New York, New York
    Weill Cornell Medicine
Mar 29, 2022

Marginal Zone Lymphoma, Follicular Lymphoma Trial in Aurora (Ublituximab, Umbralisib)

Suspended
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Aurora, Colorado
    University of Colorado Hospital
Feb 22, 2022

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Ublituximab, Umbralisib, Venetoclax)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +49 more
Jan 20, 2023

Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)

Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 8, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1 Trial in Boston (Umbralisib, Rituximab)

Recruiting
  • Lymphoma
  • +6 more
  • Boston, Massachusetts
  • +1 more
Aug 31, 2020

DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Ublituximab, Umbralisib, Bendamustine)

Terminated
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
Jul 20, 2022

B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Loncastuximab Tesirine
  • +4 more
  • Pembroke Pines, Florida
  • +19 more
Jul 22, 2022

Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in United States (TGR-1202, TGR-1202 + Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +16 more
Jul 20, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in United States (Bendamustine

Suspended
  • Grade 1 Follicular Lymphoma
  • +4 more
  • Bendamustine Hydrochloride
  • +13 more
  • Anchorage, Alaska
  • +422 more
Feb 2, 2023